Skip to main content
. 2003 Mar;41(3):1135–1142. doi: 10.1128/JCM.41.3.1135-1142.2003

TABLE 3.

Susceptibility test results for staphylococci

Class and drug No. of isolates Breakpoint standard No. in interpretive categorya
Result (%)
S I R EA CA mE ME VME
Glycopeptides
    Vancomycin 286 NCCLS 286 97.6 99.3 0.7 0.0
    Teicoplanin 275 NCCLS 272 1 2 95.3 100.0 0.0 0.0 0.0
MLS
    Azithromycin 272 NCCLS 128 9 135 87.9 93.0 2.2 10.2 0.0
    Clindamycin 288 NCCLS 207 5 76 96.5 97.2 1.4 1.9 0.0
    Clarithromycin 285 NCCLS 143 1 141 91.9 95.8 0.4 7.7 0.0
    Lincomycin 281 SFM 192 6 83 93.6 97.2 0.7 3.1 0.0
    Pristinamycin 287 SFM 274 11 2 92.0 95.5 4.2 0.4 0.0
    Quinupristin-dalfopristin 288 NCCLS 287 1 86.8 98.3 0.7 1.0 0.0
    Erythromycin 265 NCCLS 126 12 127 93.6 93.6 6.4 0.0 0.0
Penicillins
    Ampicillin 274 NCCLS 56 218 67.7 98.5 0.0 7.1 0.0
    Penicillin 273 NCCLS 54 219 74.2 95.2 0.0 24.1 0.0
PNRP (oxacillin) 277 NCCLS 128 149 94.2 97.8 0.0 2.3 2.0
β-Lactam-β-lactamase inhibitor
    Amoxicillin-clavulanate 535 NCCLS 249 286 95.7 97.8 0.0 2.4 2.1
    Ampicillin-sulbactam 274 NCCLS 126 148 94.7 97.8 0.0 2.4 2.0
    Piperacillin-tazobactam 270 NCCLS 124 146 94.6 97.8 0.0 2.4 2.1
    Ticarcillin-clavulanate 264 NCCLS 55 209 88.8 98.9 0.0 5.5 0.0
Carbapenems
    Imipenem 273 NCCLS 127 146 98.4 97.8 0.0 2.4 2.1
    Meropenem 272 NCCLS 127 145 94.6 97.8 0.0 2.4 2.1
Cephems
    Cefazolin 271 NCCLS 124 147 93.0 97.4 0.4 2.4 2.0
    Cefdinir 267 NCCLS 124 143 90.5 96.3 0.7 4.0 2.1
    Cefepime 272 NCCLS 125 147 95.2 97.8 0.0 2.4 2.0
    Cefmetazole 272 NCCLS 125 147 93.0 97.8 0.0 2.4 2.0
    Cefoperazone 271 NCCLS 126 145 93.0 97.8 0.0 2.4 2.1
    Cefotaxime 274 NCCLS 128 146 90.6 97.8 0.0 2.3 2.1
    Cefotetan 264 NCCLS 121 4 139 86.3 97.7 0.4 2.5 1.4
    Cefoxitin 269 NCCLS 126 1 142 93.7 97.0 1.1 2.4 1.4
    Cefpodoxime 273 NCCLS 86 40 147 93.8 96.7 1.5 3.5 1.4
    Ceftazidime 272 NCCLS 106 20 146 91.3 96.7 1.8 1.9 1.4
    Ceftizoxime 268 NCCLS 125 2 141 91.0 97.4 0.4 2.4 2.1
    Ceftriaxone 273 NCCLS 127 146 90.2 97.1 0.4 3.9 1.4
    Cefuroxime 268 NCCLS 128 140 97.7 97.8 0.0 2.3 2.1
    Cephalothin 276 NCCLS 128 148 95.3 97.1 0.4 2.3 2.7
    Cefaclor 269 NCCLS 125 144 92.1 97.4 0.0 4.0 1.4
    Cephalexin 271 127 144 80.3 96.7 0.0 4.7 2.1
Aminoglycosides
    Amikacin 290 NCCLS 268 8 14 82.4 95.2 3.8 1.1 0.0
    Gentamicin 288 NCCLS 199 5 84 96.2 98.6 0.3 1.0 1.2
    Kanamycin 285 NCCLS 169 1 115 95.4 98.2 1.1 1.2 0.0
    Netilmicin 289 NCCLS 279 6 4 93.1 97.9 1.0 1.1 0.0
    Tobramycin 288 NCCLS 176 10 102 83.3 97.9 1.7 0.6 0.0
5-Fluoroquinolones
    Ciprofloxacin 289 NCCLS 179 4 106 97.6 99.0 0.0 0.0 2.8
    Gatifloxacin 285 NCCLS 219 55 11 97.9 100.0 0.0 0.0 0.0
    Grepafloxacin 285 NCCLS 184 1 100 96.1 96.8 2.5 0.5 1.0
    Levofloxacin 285 NCCLS 185 27 73 98.2 98.2 1.4 0.0 1.4
    Lomefloxacin 290 NCCLS 173 13 104 97.6 99.7 0.3 0.0 0.0
    Moxifloxacin 286 PHARMb 262 17 7 97.9 98.6 1.0 0.4 0.0
    Norfloxacin 287 NCCLS 175 7 105 93.7 99.3 0.7 0.0 0.0
    Ofloxacin 290 NCCLS 187 103 99.0 99.3 0.3 0.0 1.0
    Trovafloxacin 289 NCCLS 258 19 12 96.5 98.3 1.7 0.0 0.0
    Pefloxacin 287 SFM 165 14 108 98.6 99.0 0.7 0.0 0.9
Folate antagonists
    Trimethoprim 279 NCCLS 214 65 91.0 97.8 0.0 2.8 0.0
    Trimethoprim-sulfamethoxazole (SXT) 279 NCCLS 235 44 90.7 96.8 0.0 2.6 6.8
    Trimethoprim-sulfamethoxazole (STG) 263 DIN 221 11 31 92.4 94.7 3.4 1.8 3.2
Others
    Tetracycline 287 NCCLS 237 10 40 91.6 95.5 2.8 2.1 0.0
    Chloramphenicol 288 NCCLS 251 8 29 89.9 95.5 3.8 0.8 0.0
    Nitrofurantoin 287 NCCLS 287 100.0 100.0 0.0 0.0 0.0
    Fusidic acid 287 SFM 263 16 8 95.1 97.2 2.8 0.0 0.0
    Linezolid 265 NCCLS 265 96.6 100.0 0.0 0.0 0.0
    Rifampin 288 NCCLS 268 3 17 97.6 99.3 0.7 0.0 0.0
a

Abbreviations: S, susceptible; I, intermediate; R, resistant.

b

Pharmaceutical company.